OBIO insiders were on both sides of the trade this year. Buys came to roughly $280,000 (four buyers), sales to $353,000 (two sellers).
Fain Eric S (Director) made the biggest buy, worth around $83,000.
On the institutional side, 77 funds reported holding OBIO at the end of Q2 2026, and more funds bought than sold. Quarter by quarter: Last full quarter: net selling by insiders. Insiders bought in 6 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Sherman Darren | Officer | Sell | 15,000 | $6.36 | $95K | SEC |
| Sep 8, 2026 | Hochman David P | Officer | Buy | 10,000 | $4.79 | $48K | SEC |
| Sep 2, 2026 | Sherman Darren | Officer | Sell | 15,000 | $4.94 | $74K | SEC |
| Aug 28, 2026 | Sherman Darren | Officer | Buy | 2,000 | $5.33 | $11K | SEC |
| Aug 4, 2026 | Sherman Darren | Officer | Sell | 15,000 | $4.09 | $61K | SEC |
| Jul 2, 2026 | Sherman Darren | Officer | Sell | 15,000 | $4.27 | $64K | SEC |
| Jun 2, 2026 | Hochman David P | Officer | Buy | 5,000 | $3.83 | $19K | SEC |
| Jun 2, 2026 | Sherman Darren | Officer | Sell | 15,000 | $3.87 | $58K | SEC |
| May 20, 2026 | Aryeh Jason | Director | Buy | 665 | $3.75 | $2K | SEC |
| May 19, 2026 | Aryeh Jason | Director | Buy | 8,971 | $3.90 | $35K | SEC |
| May 19, 2026 | Hochman David P | Officer | Buy | 5,000 | $3.77 | $19K | SEC |
| May 18, 2026 | Fain Eric S | Director | Buy | 20,000 | $4.13 | $83K | SEC |
| Apr 29, 2026 | RTW INVESTMENTS, LP | 10% Owner | Sell | 32 | $4.13 | $132 | SEC |
| Mar 16, 2026 | Hochman David P | Officer | Buy | 10,000 | $4.29 | $43K | SEC |
| Nov 17, 2025 | Hochman David P | Officer | Buy | 5,000 | $4.07 | $20K | SEC |
In the last 12 months Orchestra BioMed Holdings, Inc. insiders made open-market purchases worth about $280,000 and sales worth about $353,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in OBIO was filed on 2026-10-02.
77 investment managers reported holding OBIO in SEC Form 13F filings for Q2 2026.
No congressional trades in OBIO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).